Response rates by type of low intensity treatment (age ≥60 y)
| Parameter . | CLAD/CLOF + LDAC . | HMA . | Other . | P . |
|---|---|---|---|---|
| N, evaluable | 36 | 21 | 77 | |
| CR | 14 (39) | 3 (14) | 3 (4) | <.001 |
| CRp | 3 (8) | 1 (5) | 6 (8) | .87 |
| CR/CRp | 17 (47) | 4 (19) | 9 (12) | <.001 |
| 4-wk mortality | 1 (3) | 1 (5) | 8 (10) | .31 |
| 8-wk mortality | 6 (17) | 5 (24) | 14 (18) | .29 |
| Parameter . | CLAD/CLOF + LDAC . | HMA . | Other . | P . |
|---|---|---|---|---|
| N, evaluable | 36 | 21 | 77 | |
| CR | 14 (39) | 3 (14) | 3 (4) | <.001 |
| CRp | 3 (8) | 1 (5) | 6 (8) | .87 |
| CR/CRp | 17 (47) | 4 (19) | 9 (12) | <.001 |
| 4-wk mortality | 1 (3) | 1 (5) | 8 (10) | .31 |
| 8-wk mortality | 6 (17) | 5 (24) | 14 (18) | .29 |
Data presented as no. (%).
CLAD, cladribine; CLOF, clofarabine; HMA, hypomethylating agent.